Abstract:Pyrazolopyrimidine derivatives, including pyrazolopyrimidines, 6-aminopyrazolopyrimidines, 6-[(formyloxy)methyl]pyrazolopyrimidines, 6-(hydroxymethyl)pyrazolopyrimidine, and 6-(aminomethyl)pyrazolopyrimidines have been successfully prepared and tested against NCI-H226, NPC-TW01, and Jurkat cancer cell lines. Among the tested pyrazolopyrimidine compounds, we found 6-aminopyrazolopyrimidines and 6-(aminomethyl)pyrazolopyrimidines with essential o-ClPh or p-ClPh substituted moieties on N-1 pyrazole ring exhibited the best IC50 inhibition activity for Jurkat cells. Furthermore, optimization of the SAR study on the C-6 position of pyrazolopyrimidine ring demonstrated that 6-(N-substituted-methyl)pyrazolopyrimidines 17b, 17d, and 19d possessed the significant IC50 inhibitory activity for the different leukemia cell lines, especially for Jurkat, K-562, and HL-60. On the other hand, further SAR inhibition and docking model studies revealed that compound 19d, which has a 3-(1H-imidazol-1-yl)propan-1-amino side-chain on the C-6 position, was able to form four hydrogen bonds with residues Ala226, Leu152, and Glu194 and specifically extended into the P1 pocket subsite with Aurora A, resulting in improved inhibitory activity almost similar to SNS-314. To explore the anti-cancer mechanism, compound 19d was measured by Western blot analysis in Jurkat T-cells, however, it showed non-responsibility to Aurora B. For the further structural modifications on the lateral chain of compound 19d, compounds 24 with longer lateral chain were designed and synthesized for testing leukemia cell lines. However, compounds 24 was significantly decrease inhibition potency against leukemia cell lines. Based on the in-vitro results, compounds 17b and 19d could be considered to be the best potential lead drug in our study for the development of new and effective therapies for leukemia treatment. On the other hand, the DHFR inhibition results indicated compound 19d possessed good inhibitory activity and better than the reported naphthalene derivative. Through further comparisons of the model superposition of three-dimensional (3D) conformations in DHFR, compound 19d presented a similar structural alignment to Methotrexate and the reported naphthalene derivative and led to similar drug-like functional relationships. As a results, compound 19d would be a potential DHFR inhibitor for anti-leukemia drug candidate.

Anti-leukemia effects of the novel synthetic 1-benzylindole derivative 21-900 in vitro and in vivo

Novel SAHA-bendamustine hybrid NL-101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia

A Novel SAHA-bendamustine Hybrid Induces Apoptosis of Leukemia Cells

Synthesis Of Novel Indirubin Derivatives And Their Effects On The Proliferation, Cell Cycle And Apoptosis In Acute Myeloblastic Leukemia Hl-60 Cells

Synthesis of Furopyrazole Analogs of 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole (YC-1) As Novel Anti-Leukemia Agents

Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways

Synthesis and Antitumor Activity of a Series of Novel N-aryl-5-(2,2,2-trifluoroethoxy)-1,5-dihydro-2H-pyrrol-2-ones Derivatives

Synthesis, design, and antiproliferative evaluation of 6-(N-Substituted-methyl)pyrazolo[3,4-d]pyrimidines as the potent anti-leukemia agents

A novel synthesized 3', 5'-diprenylated chalcone mediates the proliferation of human leukemia cells by regulating apoptosis and autophagy pathways

Optimization and Biological Evaluation of Novel 1H-Pyrrolo[2,3-c]pyridin Derivatives As Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia

Design, Synthesis and Antineoplastic Activity of Novel Hybrids of Podophyllotoxin and Indirubin Against Human Leukaemia Cancer Cells As Multifunctional Anti-Mdr Agents.

Design and Optimization of Selective and Potent CDK9 Inhibitors with Flavonoid Scaffold for the Treatment of Acute Myeloid Leukemia.

A Novel Synthetic Compound Exerts Effective Anti-Tumour Activity in Vivo Via the Inhibition of Tubulin Polymerisation in A549 Cells.

Anti-Cancer Effects of Oxygen-Atom-Modified Derivatives of Wasabi Components on Human Leukemia Cells

Superior Activity of a New Histone Deacetylase Inhibitor (Zyj-34C) in Inhibiting Growth of Human Leukemia Cells by Inducing P21waf1 Expression and Cell Cycle Arrest.

Antitumor Effects with Apoptotic Death in Human Promyelocytic Leukemia Hl-60 Cells and Suppression of Leukemia Xenograft Tumor Growth by Irinotecan Hcl

Novel indole retinoid derivative induces apoptosis and cell cycle arrest and modulates AKT and ERK signaling in HL-60 cells

A New Arylbenzofuran Derivative Functions As an Anti-Tumour Agent by Inducing Dna Damage and Inhibiting Parp Activity

Novel nitrogen mustard-artemisinin hybrids with potent anti-leukemia action through DNA damage and activation of GPx

LW-213, a Newly Synthesized Flavonoid, Induces G2/M Phase Arrest and Apoptosis in Chronic Myeloid Leukemia

Synthesis of (1,3,4-thiadiazol-2-yl)-acrylamide derivatives as potential antitumor agents against acute leukemia cells.